Cardiac amyloid burden assessment by T1 mapping predicts survival in patients with systemic AL amyloidosis -a 2 year follow-up study Methods 102 patients underwent CMR and T1 mapping pre-and post contrast. Myocardial ECV was calculated at contrast equilibrium. 54 healthy volunteers served as controls. Patients were followed up for a median duration of 23 months and survival analyses were performed. A secondary analysis compared predictive power of the following techniques: pre contrast T1, post contrast T1, ECV at equilibrium (ECVi) and ECV at 15 minutes i.e. bolus only ECV (ECVb). 
Results
ECVi and ECVb were both raised compared to normals (both ECVi and ECVb means: 0.44 ± 0.12 vs 0.25 ± 0.02 for healthy volunteers, P < 0.001), as was native T1 (1081 ms vs 954 ms, P < 0.001). All 3 tracked pre-test probability of cardiac involvement, cardiac biomarkers and systolic and diastolic dysfunction. During follow-up, 25 deaths occurred. An ECVi of > 0.44 carried a hazard ratio for death of 3.76 (95% CI: 1.50 -9.43), P = 0.005 and pre contrast T1 of > 1080 ms = HR 3.38 (95% CI: 1.21 -9.45), p = 0.020. ECVi and ECVb performed similarly. Both ECVi and ECVb were stronger predictors of survival than pre contrast T1 as assessed by the (Harrell's C statistic). Isolated post contrast T1 was non predictive.
Conclusions
Myocardial ECV (bolus or infusion technique) and pre contrast T1 in AL amyloidosis are strong predictors of mortality with ECV (however measured) being the better predictor.
